NCT00736775View on ClinicalTrials.gov

A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

May 31, 2010

Conditions

Alzheimer's Disease

Interventions

DRUG

anti-Abeta

Intravenous single and multiple doses

DRUG

placebo

Intravenous single and multiple doses

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT00736775 - A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter